Bristol-Myers Squibb Reports Strong Fourth Quarter Sales, But Gains Minimized By Write-Offs
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm’s short-term investment portfolio dinged by shaky fourth-quarter securities market.
You may also be interested in...
Bristol Restructures To Cut Costs, Transform Into Next-Generation Biopharma
Plan to achieve $1.5 billion in cost reductions by 2010 includes a 10 percent net reduction in head count.
Adnexus Buy Aimed At Enhancing Bristol’s Transformation To Biopharma Business
Acquisition valued at $430 million comes seven months after firms signed oncology development deal, which "exceeded our expectations," Bristol told "The Pink Sheet" DAILY.
Plavix Patent Upheld By Court, Blocking Generic Clopidogrel
Apotex says it will immediately appeal the decision in favor of Sanofi-Aventis/Bristol-Myers Squibb.